/

AXGN

AxoGen, Inc.Pre-market

37.11+0.98 +2.71%USD

NasdaqCM · as of Oct 12, 16:00 ET · 15m delay

Open

36.80

Prev close

36.13

Day range

35.7337.31

52-week range

15.2752.91

Volume

1.59M1.31×

Mkt cap

2.18B

P/E ttm

—

Fwd P/E

51.47

EPS ttm

-0.6700

Div yield

0.00%

Earnings

Jul 29, 2026

From 52w high

−29.86%

Price Chart

Yahoo Finance · delayed

AXGNOct 12, 2026O 36.80H 37.31L 35.72C 37.11+0.98 (+2.71%)Vol 1.61M

SMA 5045.21
SMA 20039.09

1Y change +132.08% since Oct 10, 2025 close539 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

AXGN AxoGen, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −0.30%
1 month: −11.98%
3 months: −6.03%
6 months: +10.88%
Year to date: +13.38%
1 year: +132.08%

Valuation & ownership

Market cap: 2.18B
Enterprise value: 1.90B
P/E (ttm): —
Forward P/E: 51.47
PEG ratio: 99.04
Price / book: 7.77
Price / sales (ttm): 8.67
EV / EBITDA: -318.99
EPS (ttm): -0.6700
EPS (forward): 0.7210
Beta (5y monthly): 1.17
Dividend yield: 0.00%
Payout ratio: 0.00%
Shares outstanding: 58.67M
Float: 49.06M
Short % of float: 9.14%
Short ratio (days): 3.70
Held by insiders: 1.98%
Held by institutions: 99.06%
Avg volume (3m): 1.21M
50-day average: 45.21
200-day average: 39.09
52-week change: +132.08%
S&P 500 52-week: +17.50%

Technicals (daily)

RSI (14): 31.6
vs 50-day SMA: −17.91%
vs 200-day SMA: −5.06%
50 / 200-day trend: ▲ 50 above 200
MACD vs signal: ▼ below
ATR (14) % of price: 5.08%
Realised vol (20d, ann.): 39.7%
From 52-week high: −29.86%
From 52-week low: +143.03%

ANR

Analyst Consensus

12 analysts

Consensus

Strong buy

1.25 on a 1 (strong buy) – 5 (sell) scale

Mean target

53.67

+44.62% implied

Low 48.00Median 54.00High 58.00

Recommendation trend

Now12 / 0 / 0
1m ago10 / 0 / 0

DES

About AxoGen, Inc.

Yahoo Finance profile

Axogen, Inc., together with its subsidiaries, engages in the development and commercialization of the technologies used for peripheral nerve regeneration and repair worldwide. The company offers Avance Nerve Graft, a processed nerve allograft intended for the surgical repair of peripheral nerve discontinuities; Axoguard Nerve Connector, a coaptation aid used to align and connect severed peripheral nerve ends in a tensionless repair; and Axoguard Nerve Protector, a product used to protect and wrap damaged peripheral nerves and reinforce reconstructed nerve gaps. It also provides Axoguard HA+ Nerve Protector, a surgical implant for non-constricting protection of the peripheral nerves; Axoguard Nerve Cap, a porcine submucosa ECM product; Avive+ Soft Tissue Matrix, a multi-layer amniotic membrane allograft; and Avance Method, a technique to process Avance Nerve Graft from donated human peripheral nerve tissue. In addition, the company offers peripheral nerve tissue recovery and acquisition, and testing, as well as donor medical review and release, debridement and other processing steps, packaging, and sterilization. It provides its products to hospitals, surgery centers and military hospitals, calling on surgeons, including plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and certain oral and maxillofacial surgeons through independent in-country distributors. The company is headquartered in Alachua, Florida.

Sector: Healthcare
Industry: Medical Devices
Employees: 622
Headquarters: Alachua, FL, United States
Website: axogeninc.com
Officers: Mr. Michael D. Dale

SEAS

Seasonality · AXGN

2007–2026 · monthly returns

Strongest month May +11.67%Weakest month Mar −4.27%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	6.5	-9.0	4.4	30.4	-8.6	17.0	-8.6	20.3	-17.4	-11.5			+13.4%
2025	10.5	9.9	-7.5	-12.1	-33.1	-0.4	20.6	23.3	10.5	24.6	28.9	14.2	+98.6%
2024	41.6	9.2	-23.6	-20.6	6.6	6.0	21.3	49.8	6.6	-0.1	-0.7	18.6	+141.3%
2023	-5.1	-12.9	14.5	-4.6	-5.8	7.4	-5.4	-27.5	-20.1	-24.8	74.2	4.3	−31.6%
2022	-7.0	7.2	-15.0	-8.8	33.6	-15.3	13.8	0.5	27.2	-4.2	-4.1	-8.9	+6.5%
2021	-3.1	27.4	-8.3	-7.6	8.4	6.5	-5.7	-16.2	-7.4	-3.9	-37.0	-2.1	−47.7%
2020	-30.9	0.2	-16.0	-6.2	-0.5	-4.7	23.1	4.4	-2.0	8.4	13.3	25.3	+0.1%
2019	-19.2	11.9	14.1	11.5	-10.9	-5.4	-9.2	-11.8	-21.3	-0.3	39.3	3.2	−12.4%
2018	-1.8	5.0	25.0	9.0	23.4	2.3	-10.6	-2.4	-16.0	1.2	-10.2	-39.0	−27.8%
2017	21.1	-4.1	0.0	16.7	21.7	12.8	-5.7	11.4	9.9	6.2	29.9	6.0	+214.4%
2016	-0.8	4.8	3.1	8.6	-4.5	23.7	-2.3	34.1	0.2	-2.0	-5.6	7.8	+80.0%
2015	-4.2	-7.8	10.4	-2.9	-10.0	2.6	9.2	38.5	-13.3	12.9	18.3	-9.1	+39.3%
2014	-10.2	0.2	-24.5	-16.7	-0.8	10.3	-14.0	6.3	-3.9	13.5	1.8	27.3	−20.0%
2013	29.6	12.9	-8.6	30.7	-10.0	2.1	-2.1	-23.8	37.0	0.2	-11.2	13.7	+66.3%
2012	21.1	-12.5	-5.6	41.5	-12.3	-10.4	-8.3	10.9	-11.5	7.4	-6.9	0.0	0.0%
2011	-14.0	0.0	-8.3	-5.5	15.4	0.0	-21.3	-13.1	22.0	13.6	5.6	-10.0	−22.6%
2010	-0.5	-6.3	-17.3	5.2	-3.4	-5.1	27.1	-6.6	-1.4	-10.0	-4.1	15.6	−13.2%
2009	25.5	44.9	-5.0	-5.3	-11.1	-12.5	18.6	-14.5	25.4	5.6	-25.5	14.9	+46.2%
2008	34.6	20.0	-16.2	64.2	-10.0	-9.6	74.5	5.4	-1.6	-23.5	8.3	-21.9	+111.5%
2007	0.0	0.0	7.7	42.9	225.0	47.7	-8.3	-17.0	-21.9	-8.4	-4.2	-48.0	+100.0%

INSD

Insider Activity · AXGN

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

219.1K shares

Sells, 6 months

136.5K shares

Net shares

+82.7K

Net change in insider shares

+8.40%

Date	Insider	Transaction	Shares	Value
Sep 1, 2026	Tyndall Joseph ADirector	Sale at price 49.70 per share.	3.5K	$173.94K
Aug 10, 2026	Mcbride-Wendell Amy A.Director	Sale at price 48.42 per share.	13.4K	$646.59K
Aug 10, 2026	Mcbride-Wendell Amy A.Director	Conversion of Exercise of derivative security at price 14.85 per share.	13.4K	$198.29K
Aug 9, 2026	Began Marc A.General Counsel	Sale at price 47.34 per share.	67.5K	$3.20M
Aug 9, 2026	Began Marc A.General Counsel	Conversion of Exercise of derivative security at price 8.16 per share.	67.5K	$550.80K
Aug 6, 2026	Weiler Kathy JohnsonDirector	Sale at price 45.30 per share.	14.2K	$640.97K
Jun 17, 2026	Burke William P.Director	—	14.2K	—
Jun 17, 2026	Levine Alan M.Director	—	14.2K	—
Jun 17, 2026	Tyndall Joseph ADirector	—	14.2K	—
Jun 17, 2026	Weiler Kathy JohnsonDirector	—	14.2K	—
Jun 17, 2026	Thomas Paul GDirector	—	18.9K	—
Jun 17, 2026	Mcbride-Wendell Amy A.Director	—	14.2K	—
Jun 17, 2026	Johnson John H.Director	—	14.2K	—
May 7, 2026	Mcbride-Wendell Amy A.Director	Sale at price 42.60 per share.	1.6K	$70.16K
May 7, 2026	Mcbride-Wendell Amy A.Director	Conversion of Exercise of derivative security at price 14.85 per share.	1.6K	$24.46K
May 6, 2026	Weiler Kathy JohnsonDirector	Sale at price 44.09 per share.	16.3K	$720.62K
May 6, 2026	Weiler Kathy JohnsonDirector	Conversion of Exercise of derivative security at price 6.95 per share.	16.3K	$113.59K
May 6, 2026	Kemp Jens SchroederOfficer	Sale at price 43.44 per share.	4K	$173.76K
May 6, 2026	Hartley Lindsey MarieChief Financial Officer	Sale at price 43.67 per share.	1.1K	$45.90K
May 6, 2026	Hartley Lindsey MarieChief Financial Officer	Conversion of Exercise of derivative security at price 8.20 - 8.27 per share.	5.5K	$45.00K

AXGN

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

AXGN

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About AxoGen, Inc.

Seasonality · AXGN

Insider Activity · AXGN

Congress Trades · AXGN

Investors Holding AXGN

Investors Holding AXGN

Congress Trades · AXGN

Insider Activity · AXGN

Seasonality · AXGN

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About AxoGen, Inc.

Financial Snapshot

Earnings & Dividends

News